KILL New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

 

Genentech requests that their press release NewsItemId: 20240125093104 “New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)” be killed.

The release was issued prematurely by Genentech.

A replacement release will be issued at a later date.

Contacts

Media Contact:

Shirley Dang, (650) 467-6800

Advocacy Contact:

Danielle Haney, (240) 805-4810

Investor Contacts:

Loren Kalm, (650) 225-3217

Bruno Eschli, +41 61 687 5284

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  259.30
+5.24 (2.06%)
AAPL  333.60
-6.82 (-2.00%)
AMD  612.53
-8.15 (-1.31%)
BAC  53.70
+0.09 (0.17%)
GOOG  347.97
+3.11 (0.90%)
META  721.89
+1.00 (0.14%)
MSFT  531.84
+9.23 (1.77%)
NVDA  230.69
+0.22 (0.09%)
ORCL  141.89
+6.70 (4.96%)
TSLA  387.01
+12.01 (3.20%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.